Composition of BTK inhibitor
By combining BTK inhibitors with liquid capsules, using suitable oil phase, surfactants and cosolvents, the problem of low bioavailability of existing BTK inhibitors is solved, and higher drug absorption and therapeutic effects are achieved.
Patent Information
- Application Number
- CN202310584796.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-23
- Publication Date
- 2024-11-26
AI Technical Summary
The existing BTK inhibitors have problems such as poor water solubility, obvious first pass effect and low bioavailability in clinical applications, resulting in large fluctuations in blood drug concentrations and affecting the efficacy.
Combining BTK inhibitors with liquid capsules, using suitable oil phases, surfactants and co-solvents, prepare liquid capsules with high drug loading, stable quality and uniform particle size distribution, and improve the bioavailability of the drug .
It significantly improves the absorption of drugs and enrichment effects in the lesion site, improves oral bioavailability, reduces adverse reactions, and enhances the therapeutic effect.
Smart Images

Figure BDA0004242881570000011 
Figure BDA0004242881570000071 
Figure BDA0004242881570000081
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of pharmaceutical preparations, and in particular, relates to a composition of BTK inhibitors. Background Art
[0002] BTK (Bruton's tyrosine kinase) is a non-receptor, cytoplasmic tyrosine protein kinase in the Tec family. It is involved in the transduction of TLR, BAFF-R, BCR and CXCR4 / 5 signals, and in regulating the proliferation, differentiation, apoptosis and migration of B cells. BTK plays an important role in the pathogenesis of malignant B-cell lymphoma, and BTK inhibitors are important drugs for the treatment of B-cell lymphoma.
[0003] At present, a variety of BTK inhibitors have been clearly confirmed in clinical trials that they have an efficacy that surpasses traditional chemotherapy for the most common lymphoma, malignant B-cell lymphoma. The launch of the world's first BTK inhibitor, ibrutinib, has changed the treatment model for CLL and MCL. It can be treated orally and achieve relatively lasting remission. Currently available BTK inhibitors include ibrutinib, acalabrutinib, zanubrutinib, tirabrutinib, orelabrutinib and pirtobrutinib, and their structural formulas are shown below:
[0004]
[0005] The long-term efficacy of BTK inhibitors has been confirmed, but there are still some shortcomings. For example, poor water solubility and obvious first-pass effect lead to low absolute bioavailability. For example, the human bioavailability of ibrutinib is only 2.9%; the peak time and elimination half-life of blood drugs in the body are both short, resulting in large fluctuations in blood drug concentrations. Once adverse reactions such as bleeding and bone marrow suppression occur when using BTK inhibitors, the dose must be adjusted or even treatment must be terminated. Due to its rapid absorption and elimination, the blood drug concentration fluctuates greatly, which directly affects the efficacy of the drug.
[0006] Therefore, it is necessary to provide a preparation composition for BTK inhibitors to further improve the bioavailability of the drug. Summary of the invention
[0007] In order to overcome the deficiencies in the prior art, the present invention ingeniously combines the physicochemical properties of BTK inhibitors with liquid capsules, and by selecting appropriate content oil phase, surfactant and cosolvent, prepares BTK inhibitor liquid capsules with high drug loading, stable quality and uniform particle size distribution, which greatly improves the bioavailability of the drug, while enabling the drug to reach the lesion site faster, achieving a better therapeutic effect.
[0008] In order to achieve the above object, the present invention adopts the following technical solution:
[0009] The present invention provides a composition of a BTK inhibitor for preparing a liquid capsule preparation of the drug, wherein the composition comprises a BTK inhibitor raw material, an oil phase, a surfactant and a cosolvent, or the composition does not comprise a cosolvent.
[0010] The BTK inhibitor API is selected from one of ibrutinib, acalabrutinib, zanubrutinib, tilarabrutinib, obeticholic acid, and pyruvic acid.
[0011] The oil phase is selected from one or more of glycerol esters, ethylene glycol esters, and propylene glycol esters of long-chain fatty acids and medium-chain fatty acids, and includes at least one ester of long-chain fatty acids, wherein:
[0012] The esters of long-chain fatty acids include, but are not limited to, vitamin E polyethylene glycol succinate, glyceryl monostearate, stearoyl polyoxyethylene (32) glyceride, glyceryl monooleate, glyceryl monolinoleate;
[0013] The esters of medium-chain fatty acids include, but are not limited to, polyoxyethylene (8) caprylic / capric glyceride, tricaprylic glyceride, monocaprylic glyceride, lauroyl polyoxyethylene (32) glyceride, medium-chain triglycerides, propylene glycol monocaprylate, propylene glycol monolaurate, and caprylic / capric glyceride.
[0014] Furthermore, the oil phase is preferably a long-chain fatty acid glyceride, including but not limited to one or more of monostearic acid glyceryl, stearyl polyoxyethylene (32) glyceride, monooleic acid glyceryl, and monolinoleic acid glyceryl.
[0015] More preferably, the oil phase is a combination of long-chain fatty acid glycerides, including but not limited to a combination of monostearic acid glyceryl, stearyl polyoxyethylene (32) glyceride, monooleic acid glyceryl, and monolinoleic acid glyceryl; specifically, it is preferably a combination of monostearic acid glyceryl and stearyl polyoxyethylene (32) glyceryl, a combination of monostearic acid glyceryl and monooleic acid glyceryl, a combination of monostearic acid glyceryl and monolinoleic acid glyceryl, or a combination of monooleic acid glyceryl and monolinoleic acid glyceryl; the long-chain fatty acid glycerides are combined in any proportion.
[0016] Further, the oil phase is preferably a combination of long-chain fatty acid glycerides and medium-chain fatty acid glycerides, including but not limited to one or more of monostearic acid glyceryl, monooleic acid glyceryl, monolinoleic acid glyceryl and one or more of monocaprylic acid glyceryl, tricaprylic acid glyceryl, lauroyl polyoxyethylene (32) glyceride, medium-chain triglycerides, and caprylic acid glyceryl. Specifically, preferably, the combination of monostearic acid glyceryl and monocaprylic acid glyceryl, the combination of monostearic acid glyceryl and tricaprylic acid glyceryl, the combination of monooleic acid glyceryl and monocaprylic acid glyceryl, the combination of monooleic acid glyceryl and tricaprylic acid glyceryl, the combination of monooleic acid glyceryl and caprylic acid glyceryl, the combination of monolinoleic acid glyceryl and monocaprylic acid glyceryl, the combination of monolinoleic acid glyceryl and tricaprylic acid glyceryl, or the combination of monolinoleic acid glyceryl and caprylic acid glyceryl.
[0017] Furthermore, the volume ratio of the long-chain fatty acid glyceride to the medium-chain fatty acid glyceride is 1:10 to 4:1, preferably 1:4 to 4:1.
[0018] Furthermore, the volume of the long-chain fatty acid glycerides is greater than that of the medium-chain fatty acid glycerides, and the volume ratio of the long-chain fatty acid glycerides to the medium-chain fatty acid glycerides is 1 to 4:1, preferably 2 to 4:1, and more preferably 2 to 3:1.
[0019] The surfactant is selected from one or more of artificially synthesized polyhydroxy polymer compounds, and the polyhydroxy polymer compounds include but are not limited to: polyoxyethylene 40 hydrogenated castor oil, propylene glycol monocaprylate, poloxamer 188, polysorbate 80, polyoxyethylene ether (35) castor oil, polyoxyethylene ether (40) castor oil, 15-hydroxystearate polyethylene glycol ester, Span 80, oleoyl polyoxyethylene glyceride, and polyglycerol oleate.
[0020] Furthermore, the surfactant is selected from one or more of propylene glycol monocaprylate, polysorbate 80, polyoxyethylene ether (35) castor oil, polyoxyethylene ether (40) castor oil, 15-hydroxystearate polyethylene glycol ester, Span 80, and oleoyl polyoxyethylene glyceride.
[0021] Furthermore, the surfactant is preferably a combination of one or more of 15-hydroxystearate polyethylene glycol, Span 80, oleoyl polyoxyethylene glyceride, polysorbate 80 and one or more of polyoxyethylene ether (35) castor oil and polyoxyethylene ether (40) castor oil; specifically, preferably a combination of 15-hydroxystearate polyethylene glycol and polyoxyethylene ether (35) castor oil, a combination of Span 80 and polyoxyethylene ether (35) castor oil, a combination of oleoyl polyoxyethylene glyceride and polyoxyethylene ether (35) castor oil, a combination of polysorbate 80 and polyoxyethylene ether (35) castor oil, a combination of 15-hydroxystearate polyethylene glycol and polyoxyethylene ether (40) castor oil, a combination of Span 80 and polyoxyethylene ether (40) castor oil, a combination of oleoyl polyoxyethylene glyceride and polyoxyethylene ether (40) castor oil, or a combination of polysorbate 80 and polyoxyethylene ether (40) castor oil.
[0022] Furthermore, in the combination of surfactants, the volume ratio of the former one or more of 15-hydroxystearate polyethylene glycol ester, Span 80, oleoyl polyoxyethylene glyceride, polysorbate 80 and the latter one or more of polyoxyethylene ether (35) castor oil and polyoxyethylene ether (40) castor oil is 1:5 to 5:1, preferably 1:4 to 4:1, 1:3 to 3:1, 1:2 to 2:1 or 1:1.
[0023] The cosolvent is selected from one or more of low molecular weight alcohols or synthetic ether polymer molecules, and the low molecular weight alcohols or synthetic ether polymer molecules include but are not limited to hexylene glycol, propylene glycol, glycerol, ethanol, diethylene glycol monoethyl ether, polyethylene glycol 400, polyethylene glycol 1500, polyethylene glycol 3350, and polyethylene glycol 6000.
[0024] Furthermore, in the composition of the BTK inhibitor, except for the BTK inhibitor API, the mass ratios of the oil phase, surfactant and cosolvent are 20% to 80%, 20% to 80%, and 0% to 30%, respectively, preferably 28% to 60%, 28% to 60%, and 0% to 30%; 32% to 60%, 32% to 60%, and 0% to 20%; or 40% to 60%, 40% to 60%, and 0% to 10%.
[0025] Furthermore, in the composition of the BTK inhibitor, excluding the BTK inhibitor API, the mass proportion of the oil phase is 20%, 28%, 30%, 32%, 35%, 40%, 42%, 48%, 50%, 54%, 60%, 70% or 80%; the mass proportion of the surfactant is 20%, 28%, 30%, 32%, 35%, 40%, 42%, 48%, 50%, 54%, 60%, 70% or 80%; the mass proportion of the co-solvent is 0%, 10%, 20% or 30%.
[0026] Furthermore, the content of the BTK inhibitor API in the BTK inhibitor composition is 0.1% to 10%, preferably 1% to 8%, more preferably 1% to 6% or 2% to 4%, and the content refers to the ratio of the mass of the API to the total mass of the oil phase, surfactant and co-solvent.
[0027] Furthermore, the content of BTK inhibitor API in the BTK inhibitor composition is 1%, 2%, 2.5%, 3%, 3.5%, 4%, 5%, 6%, 7% or 8%.
[0028] Preferably, the amount of the BTK inhibitor API added to the composition is (5-60) mg / ml, where the amount added refers to the ratio of the mass of the API to the total volume of the oil phase, surfactant and co-solvent.
[0029] The second aspect of the present invention is to provide a liquid capsule preparation of a composition comprising the BTK inhibitor, wherein the preparation is a liquid hard capsule or a liquid soft capsule, and is an oral dosage form.
[0030] The third aspect of the present invention is to provide a method for preparing the contents of the liquid capsule preparation, wherein the preparation method comprises taking an oil phase, an emulsifier and a cosolvent, adding a BTK inhibitor API, and stirring the mixture thoroughly. Specifically, the BTK inhibitor API can be first dissolved in the oil phase and the cosolvent, and then a surfactant is added and stirred thoroughly.
[0031] Furthermore, the method for preparing the contents of the liquid capsule preparation specifically comprises the following steps:
[0032] (1) Oil phase mixing: weigh the prescribed amount of oil phase and co-solvent components into a beaker, stir with a stirring paddle until the mixture is uniform and set aside;
[0033] (2) Dissolving the API: Slowly add the prescribed amount of the BTK inhibitor API to the solution of step (1) and stir until the API is dissolved;
[0034] (3) Adding surfactant: After weighing the prescribed amount of surfactant and mixing evenly, add it to the solution in step (2), and continue stirring until the mixture is evenly mixed;
[0035] (4) Filtration: Filter the solution in step (3) using a 0.45 μm filter;
[0036] (5) Filling: Fill the filtered solution into capsules; liquid hard capsules also need to be sealed.
[0037] The fourth aspect of the present invention is to provide the use of the liquid capsule preparation for preparing medicines for treating blood diseases such as lymphoma and lymphocytic leukemia.
[0038] Compared with the prior art, the present invention has the following beneficial effects:
[0039] The liquid capsule preparation of BTK inhibitor provided by the present invention has high drug loading, stable quality, and uniform particle size distribution, which greatly improves the absorption of the drug and enriches it at the lesion site, achieving a better therapeutic effect, and provides an oral administration solution for poorly soluble drugs; the preparation can achieve higher oral bioavailability, and the blood drug exposure of the preparation is significantly improved compared with direct administration of the raw material drug. The present invention also provides a preparation method of the liquid capsule, which has a wide range of application prospects.
[0040] Taking ibrutinib as an example, the saturated solubility in the blank self-microemulsion is 6%; there is no stratification phenomenon, and it has excellent static stability, dilution stability and storage period. DETAILED DESCRIPTION
[0041] The technical scheme of the present invention is clearly and completely described below with specific embodiments. It should be understood that the described embodiments are only part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of the present invention.
[0042] The BTK inhibitors used in the following examples can be prepared by methods reported in the prior art or purchased commercially.
[0043] -Prepare simulated gastric fluid SGF: Add 950 ml of water to a 1000 ml volumetric flask, then add 1.4 ml of concentrated hydrochloric acid and 2 g of sodium chloride to dissolve completely, and then add water to make up to volume to obtain a buffer solution. Take a 100 ml volumetric flask, add 5.97 mg of FaSSIF / FeSSIF / FaSSGF powder, and use 100 ml of the above buffer solution to dissolve completely and then make up to volume.
[0044] -Prepare fasting artificial intestinal fluid FaSSIF: Add 0.042 g of sodium hydroxide granules, 0.3438 g of sodium dihydrogen phosphate monohydrate, and 0.6186 g of sodium chloride to a 100 ml volumetric flask, dissolve in 90 ml of water, adjust pH to 6.5, and make up to volume with water to obtain a buffer solution. Take a 100 ml volumetric flask, add 0.224 g of FaSSIF / FeSSIF / FaSSGF powder, dissolve completely with 50 ml of the above buffer solution, and then make up to volume.
[0045] Example 1
[0046] Preparation method: first prepare the oil phase, surfactant and cosolvent in proportion for use. Accurately measure the prescribed amount of oil phase and cosolvent, stir with a stirring paddle, slowly add the prescribed amount of BTK inhibitor, stir to obtain a clear oil phase solution, then accurately measure the surfactant and add it to the oil phase solution, continue stirring for about 20 minutes until all components are mixed, and obtain the BTK inhibitor composition, wherein:
[0047] The oil phase is selected from glyceryl monooleate: glyceryl tricaprylate in a ratio of 2:1; the surfactant is selected from polysorbate 80: polyoxyethylene ether (40) castor oil in a ratio of 1:1; and no cosolvent is added.
[0048] The mass ratios of the oil phase, the surfactant and the co-solvent are 40%, 60% and 0% respectively.
[0049] The BTK inhibitor is ibrutinib, and the content of the BTK inhibitor in the composition is 2%.
[0050] The BTK inhibitor composition is dispersed in simulated gastric fluid SGF and simulated intestinal fluid FaSSIF respectively,
[0051] Results of dispersion experiment of SGF in simulated gastric fluid: clarification;
[0052] Results of FaSSIF dispersion experiment in simulated intestinal fluid: clarification.
[0053] Example 2-34
[0054] The operation of Example 2-34 is the same as that of Example 1, the BTK inhibitor is selected from ibrutinib, and other prescription options are shown in Table 1-3:
[0055] Table 1
[0056]
[0057]
[0058] The dispersion test results of the compositions in Examples 2-22 in Table 1 in simulated gastric fluid SGF and simulated intestinal fluid FaSSIF were all clear.
[0059] Table 2
[0060]
[0061] The dispersion test results of the compositions in Examples 23-28 in Table 2 in simulated gastric fluid SGF were all emulsions; the dispersion test results in simulated intestinal fluid FaSSIF were clear, and the clear liquids in Examples 26-28 had opalescence.
[0062] Table 3
[0063]
[0064] The dispersion test results of the compositions in Examples 29-34 in Table 3 in simulated gastric fluid SGF and simulated intestinal fluid FaSSIF all showed that the compositions were in the form of emulsions.
[0065] According to the dispersion test results in Examples 1-34, the dispersion effect of the composition in Example 1-22 in simulated gastric fluid SGF and simulated intestinal fluid FaSSIF is better than that of Examples 23-28, and Examples 23-28 are better than that of Examples 29-34.
[0066] Comparative Examples 1-8
[0067] The operation of Comparative Examples 1-8 is the same as that of Example 1, the BTK inhibitor is selected from ibrutinib, and other prescriptions are selected as shown in Table 4:
[0068] Table 4
[0069]
[0070]
[0071] The dispersion test results of the composition in the comparative example in the simulated gastric fluid SGF and the simulated intestinal fluid FaSSIF showed that the composition could not be dispersed evenly or had precipitation.
[0072] Example 35 Pharmacokinetics in rats
[0073] Instrument: LC-MS / MS-DG_Triple Quad 6500plus.
[0074] Chromatographic conditions: Chromatographic column ACQUITY UPLC HSS T3 1.8μm 2.1×50mm, column temperature 45°C. The mobile phase consisted of 0.1% formic acid aqueous solution (A) and 0.1% formic acid acetonitrile solution (B), and the gradient was shown in Table 5 below:
[0075] Table 5
[0076] Gradient Table Time Flow Rate(mL / min) %A %B initial 0.600 85.0 15.0 0.2 0.600 85.0 15.0 1 0.600 0.0 100.0 1.4 0.600 0.0 100.0 1.41 0.600 85.0 15.0 1.5 0.600 85.0 15.0
[0077] Retention time:
[0078] Ibrutinib: 0.97 min
[0079] Verapamil: 0.83min
[0080] Mass spectrometry conditions: SRM detection, the detection ions of each compound are as follows:
[0081] Ibrutinib: [M+H]+m / z:441.2 / 138.2
[0082] Verapamil:[M+H]+m / z:455.2 / 164.9
[0083] Experimental animals: Male SD rats, weighing 212-252 g.
[0084] Drug preparation: The example preparations were accurately prepared according to different prescriptions, with a dosage of 15.0 mg / kg, administered by oral gavage, and prepared before administration. The ibrutinib bulk drug control group was dissolved in an aqueous solution of 0.5% methylcellulose / 0.2% polysorbate 80, with a dosage of 15.0 mg / kg, administered by oral gavage, and prepared before administration.
[0085] Animal drug administration and blood collection: SD rats were intragastrically administered, and blood was collected before and 5min, 15min, 30min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, and 24h after administration. The blood was placed in an ice bath and centrifuged to prepare plasma, which was frozen.
[0086] Blood drug concentration data and pharmacokinetic parameter calculation:
[0087] Phoenix WinNonlin 6.3 software was used to calculate and analyze the pharmacokinetic parameters, and the unit of blood drug concentration was ug / L.
[0088] After absorption, Ibrutinib quickly enters the plasma, and the pharmacokinetics test results of Ibrutinib are shown in Table 6. The preparation of the present invention can achieve higher oral bioavailability, and the blood drug exposure of the preparation is significantly improved compared with direct administration of the raw material drug, and has a wide range of application prospects.
[0089] Table 6 Pharmacokinetic parameters of Ibrutinib in rats
[0090]
[0091] This application is described in detail for the purpose of enabling those skilled in the art to understand the contents of this application and implement them. This is not intended to limit the scope of protection of this application. Any equivalent changes or modifications made according to the spirit of this application should be included in the scope of protection of this application.
Claims
1. A composition of a BTK inhibitor, characterized in that: The composition includes a BTK inhibitor drug substance, an oil phase, a surfactant and a cosolvent, or the composition does not include a cosolvent; The BTK inhibitor API is selected from one of ibrutinib, acalabrutinib, zanubrutinib, tilarabrutinib, orelabrutinib and pyruvicinib; The oil phase is selected from one or more of glycerol esters, ethylene glycol esters, and propylene glycol esters of long-chain fatty acids and medium-chain fatty acids, and includes at least one glycerol ester, ethylene glycol ester, or propylene glycol ester of long-chain fatty acids; The surfactant is selected from one or more polyhydroxy polymer compounds.
2. The BTK inhibitor composition according to claim 1, characterized in that The oil phase is selected from one or more of monostearic acid glyceryl, stearoyl polyoxyethylene (32) glyceride, monooleic acid glyceryl, monolinoleic acid glyceryl, polyoxyethylene (8) caprylic / capric glyceride, tricaprylic acid glyceryl, monocaprylic acid glyceryl, lauroyl polyoxyethylene (32) glyceride, medium-chain triglycerides, propylene glycol monocaprylate, propylene glycol monolaurate, and caprylic / decanoic acid glyceryl, and includes at least one ester of a long-chain fatty acid.
3. The BTK inhibitor composition according to claim 1, characterized in that The oil phase is long-chain fatty acid glyceride, including one or a combination of monostearic acid glyceryl, stearyl polyoxyethylene (32) glyceride, monooleic acid glyceryl, and monolinoleic acid glyceryl.
4. The BTK inhibitor composition according to claim 1, characterized in that The oil phase is a combination of long-chain fatty acid glycerides and medium-chain fatty acid glycerides, including one or more of monostearic acid glyceryl, monooleic acid glyceryl, monolinoleic acid glyceryl and one or more of monocaprylic acid glyceryl, tricaprylic acid glyceryl, lauroyl polyoxyethylene (32) glyceride, medium-chain triglycerides, and caprylic-decanoic acid glyceryl; the volume ratio of the long-chain fatty acid glycerides to the medium-chain fatty acid glycerides is 1:10 to 4:1, preferably 1:4 to 4:
1.
5. The BTK inhibitor composition according to claim 1, characterized in that The surfactant is selected from one or more of polyoxyethylene 40 hydrogenated castor oil, propylene glycol monocaprylate, poloxamer 188, polysorbate 80, polyoxyethylene ether (35) castor oil, polyoxyethylene ether (40) castor oil, 15-hydroxystearate polyethylene glycol ester, Span 80, oleoyl polyoxyethylene glyceride, and polyglycerol oleate.
6. The BTK inhibitor composition according to claim 5, characterized in that The surfactant is a combination of one or more of 15-hydroxystearate polyethylene glycol, Span 80, oleoyl polyoxyethylene glyceride, polysorbate 80 and one or more of polyoxyethylene ether (35) castor oil and polyoxyethylene ether (40) castor oil; the volume ratio of the two components is 1:5 to 5:1, preferably 1:3 to 3:
1.
7. The BTK inhibitor composition according to claim 1, characterized in that: The cosolvent is selected from one or more low molecular weight alcohol or ether polymer molecules.
8. The BTK inhibitor composition according to claim 1, characterized in that In the composition, except for the BTK inhibitor API, the mass ratios of the oil phase, the surfactant and the cosolvent are 28% to 60%, 28% to 60%, and 0% to 30%, respectively; preferably 32% to 60%, 32% to 60%, and 0% to 20%; more preferably 40% to 60%, 40% to 60%, and 0% to 10%.
9. The BTK inhibitor composition according to claim 1, characterized in that: The content of the BTK inhibitor API in the composition is 0.1% to 10%, preferably 1% to 8%, and more preferably 1% to 6%.
10. A liquid capsule preparation, characterized in that: A composition comprising any one of the BTK inhibitors described in claims 1-9, wherein the preparation is a liquid hard capsule or a liquid soft capsule.
11. The method for preparing the contents of the liquid capsule preparation according to claim 10, characterized in that: The preparation method comprises the steps of first dissolving the BTK inhibitor raw material in an oil phase and a co-solvent, and then adding a surfactant and stirring the mixture evenly.
12. The use of the liquid capsule preparation according to claim 10, characterized in that: Used to prepare drugs for treating lymphoma and lymphocytic leukemia.
